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 Introduction 
 Parenteral nutrition (PN) has revolutionized the 
nutritional care of patients who cannot fully use 
the gastrointestinal tract [ 1 ]. Today more than 
30,000 patients, young and old, depend on long- 
term PN for survival, and more than 350,000 
patients in the USA receive PN on a yearly basis 
[ 2 ]. Despite its common usage, PN is associated 
with a number of signifi cant morbidities. Parenteral 
nutrition-associated liver disease (PNALD) has 
become one of the most challenging complica-
tions associated with prolonged administration of 
PN. As PNALD progresses to a more permanent 
injury to the liver, patients are at high risk of addi-
tional morbidity and even mortality [ 3 ,  4 ]. A num-
ber of recognized risk factors have been attributed 
to PNALD, but it appears that no single factor is 
fully responsible as a causative agent or factor. 
Thus, the multifactorial nature of PNALD has 
been an incredible challenge to both clinicians and 
researchers, and the process unfortunately remains 
incompletely understood. This chapter discusses 
the current knowledge of PNALD, the potential 
causative factors, as well as treatment and preven-
tive strategies. 
 Background 
 Parenteral nutrition (PN) describes the intravenous 
administration of complete and balanced nutrition 
in order to support anabolism and maintain or pro-
mote weight gain whenever the gastrointestinal 
tract cannot and should not be used for adequate 
nutrition in patients with or at risk for malnutri-
tion. PN is composed of the energy- yielding mac-
ronutrients [amino acids, dextrose, intravenous fat 
emulsions (IVFEs)], micronutrients (vitamins and 
trace elements), electrolytes, and fl uids. PN com-
ponents are tailored to individual patient needs 
based on nutritional status and nutritional require-
ments, underlying clinical conditions, concomi-
tant medication therapy, and laboratory and 
diagnostic parameters [ 5 ]. Although PN is a life-
saving therapy in patients with intestinal failure, it 
can be associated with infectious and metabolic 
complications. PNALD is one of the most 
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 challenging and morbid complications associated 
with PN. PNALD is typically associated with 
long-term PN use and includes cholestasis, steato-
sis, and cholelithiasis. This chapter reviews the 
epidemiology, risk factors, and etiologies of 
PNALD and discusses the different approaches to 
its prevention and treatment. 
 Epidemiology 
 The reported overall frequency of PNALD in 
clinical studies varies from 7.4 to 84 %. This 
wide variation is due to the heterogeneity of 
study subjects, differences in the defi nition of 
PNALD, and the variation in the composition 
and duration of PN therapy. For instance, overall 
liver complications were reported in 40–60 % of 
home-dependent PN children [ 6 ], whereas 33 % 
of premature infants who received PN for more 
than 7 days reportedly developed PNALD [ 7 ]. In 
another study of premature neonates (median 
gestational age of 26 weeks), the frequency of 
PNALD was considerably higher and ranged 
from 56 to 85 % [ 8 ]. In a retrospective review of 
176 premature infants who received PN, cho-
lestasis occurred in 24 % of infants especially in 
those with lower gestational age (34 vs. 36 weeks; 
 p < 0.01) and those who received longer duration 
of PN (76 vs. 21 days;  p < 0.001) [ 9 ]. 
 Clinical Features 
 A transient elevation of liver transaminases and 
alkaline phosphatase may occur within 1–2 weeks 
of PN initiation, but levels return to normal upon 
termination of PN without necessarily denoting 
permanent liver damage. However, prolonged 
PN use increases the risk for severe liver disease 
that may progress to liver failure if not appropri-
ately addressed [ 10 ,  11 ]. 
 Histopathology 
 The liver histologic changes related to PN vary in 
relation to the extent and type of PNALD. Patho-
logic features may include portal infl ammation, 
canalicular and intralobular cholestasis, peripor-
tal infl ammation, pseudoacinar formation, por-
tal-portal bridging, steatosis, portal and 
pericellular fi brosis, and cirrhosis [ 12 ,  13 ]. Some 
of the earlier processes of PNALD are discussed 
below. 
 Steatosis 
 Hepatic steatosis, or fat accumulation in the 
hepatocytes, is mostly the result of excessive 
carbohydrate administration. Excess dextrose 
increases insulin levels, and when the amount of 
carbohydrates exceeds the metabolic rate of the 
substrate, this results in carbohydrate conversion 
to fat (lipogenesis) in the hepatocytes. 
Overfeeding from intravenous fat emulsion may 
also cause hepatic steatosis by causing excessive 
fat accumulation in the liver, but is a far less 
common process. Other possible causes may 
include choline and carnitine defi ciencies. 
Hepatic steatosis is mostly asymptomatic and 
liver transaminases are poor clinical markers of 
the degree of fatty infi ltration [ 14 ]. Therefore, 
the diagnosis of hepatic steatosis is mostly inci-
dental but should be ruled out in PN-dependent 
patients who present with malaise, abdominal 
pain, and hepatomegaly. Hepatic steatosis can be 
reversed with rebalancing carbohydrate and 
IVFE intake and through avoidance of overfeed-
ing before advanced liver disease occurs. A bal-
anced PN typically provides 50–60 % of total 
daily calories from dextrose; 20–30 % of calo-
ries from IVFEs, with the lipid dose not exceed-
ing 3 g/kg/day in infants and 2 g/kg/day in other 
children; and the remaining 10–20 % of calories 
from amino acids [ 15 ]. 
 Cholelithiasis 
 Cholelithiasis or gallstone formation in 
PN-dependent patients is the result of bile accu-
mulation secondary to decreased gallbladder 
contractility when fasting. The lack of oral or 
enteral feeding results in decreased secretion of 
cholecystokinin (CCK), a peptide hormone that 
is secreted in the duodenum in response to food 
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and stimulates gallbladder emptying. In the 
absence of gallbladder contractility during fast-
ing, bile accumulates in the gallbladder, which 
facilitates the formation of calcium bilirubinate 
sludge and cholesterol gallstones [ 16 ,  17 ]. 
Approximately 10 % of infants receiving chronic 
PN develop gallstone disease [ 18 ]. While the eti-
ology of cholelithiasis in PN patients was ini-
tially presumed to be due to the lack of CCK 
secretion, a prospective randomized controlled 
trial showed that treatment with cholecystokinin- 
octapeptide (CCK-OP), a synthetic peptide 
derivative of CCK, failed to reduce the incidence 
of gallstone formation [ 19 ]. This suggests that 
the etiology of these stones may actually be due 
to an abnormality of bile production itself. 
Patients with short bowel syndrome (SBS) are at 
increased risk for cholelithiasis due to impaired 
enterohepatic cycling with ileal resection, 
decreased bile fl ow during fasting, and the cana-
licular accumulation of toxic bile acids [ 20 ,  21 ]. 
Cholelithiasis may be prevented or delayed by 
early initiation of oral or enteral feeding. 
Cholecystectomy may be considered in symp-
tomatic cases. 
 Cholestasis 
 PN-associated cholestasis (PNAC) is the most 
clinically challenging form of PNALD. Its time 
to onset is diffi cult to accurately predict due to 
its association with different risk factors. In a 
retrospective study of premature infants who 
received PN, the median time to development of 
cholestasis was 23 days, with 77 % of infants 
developing cholestasis within 5 weeks of PN ini-
tiation [ 9 ]. Biochemical markers of PNAC typi-
cally include elevations of serum bilirubin and 
γ-glutamyl transpeptidase (GGT) concentra-
tions. More specifi cally, serum conjugated bili-
rubin concentrations of 2 mg/dL or higher are 
commonly used in clinical practice as a bio-
chemical marker of cholestasis [ 22 ,  23 ]. Patients 
with progressive liver disease develop jaundice, 
hepatosplenomegaly, and ascites. The presence 
of jaundice along with steady elevation of serum 
bilirubin concentrations is a predictor of higher 
mortality risk [ 4 ]. 
 Outcomes 
 While most patients with PNALD undergo reso-
lution of the condition once off PN, the disorder 
is associated with a signifi cant morbidity and 
mortality rate in those who remain on PN. Despite 
biochemical resolution of PNALD signs in most 
patients, normalized biochemical markers of 
PNALD are not always indicative of a normaliza-
tion of liver histology. Liver fi brosis may con-
tinue to be apparent despite normal biomarkers 
[ 24 ]. For those infants who have progressive 
PNALD, the disease will eventually result in 
overt liver failure and death. In a study of surgical 
neonates, almost one-third of patients died with 
long-standing PNALD [ 25 ]. In a more recent 
study of children with SBS, PNALD was the 
greatest risk factor for patient mortality [ 26 ]. 
Patients with PNALD should be treated aggres-
sively with a multimodal approach in an attempt 
to ameliorate the progression of the disease and 
to avoid invasive surgical procedures, intestinal 
transplantation, and death. For children with 
intestinal failure, a multidisciplinary approach to 
care has been associated with better outcomes. 
 Risk Factors 
 Risk factors associated with PNALD are predom-
inately related to the underlying clinical 
condition(s), but PN components (e.g., soybean- 
based intravenous fat emulsions) may also con-
tribute. Several risk factors have been identifi ed 
that contribute to PNALD including prematurity 
and low birth weight, prolonged PN duration, 
sepsis, SBS, bacterial overgrowth and transloca-
tion, bowel rest, and lack of enteral feeding [ 23 ]. 
Necrotizing enterocolitis (NEC) is a signifi cant 
risk factor for PNALD [ 27 ]. In neonates with 
NEC who underwent surgical treatment, inde-
pendent risk factors for PNALD [defi ned as 
serum direct bilirubin concentration of 2 mg/dL 
or higher, or serum  alanine aminotransferase 
( ALT ) of at least twice the upper limit of normal] 
also included small bowel resection or presence 
of a proximal jejunostomy, PN duration, and pre-
operative exposure to PN especially for 4 weeks 
or longer [ 8 ]. Gestational age and cholestasis in 
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neonates receiving PN are also independent risk 
factors to poor postnatal growth [ 28 ]. A system-
atic review of the risk factors associated with 
PNALD that was conducted by the American 
Pediatric Surgical Association Outcomes and 
Clinical Trials Committee provides a critical 
appraisal of the evidence relating the nutrient and 
non-nutrient risk factors and liver disease [ 27 ]. 
 Prematurity and low birth weight are risk fac-
tors for PNALD considering the physiologic 
immaturity of the liver excretory systems. 
PNALD was reported in 50 % of premature 
infants with a birth weight below 2,000 g [ 29 ]. 
The frequency of PNALD gradually increased 
from 1.4 to 13.7 % in infants with increasing pre-
maturity from over 36 weeks’ to before 32 weeks’ 
gestation, respectively [ 30 ]. In a study of 24 pre-
mature infants (mean gestational age of 
32.5 weeks and birth weight of 1,840 g), PN 
duration, fasting, gastrointestinal surgery, and 
maximum caloric and carbohydrate intake in PN 
were signifi cant risks of PNALD [ 7 ]. Considering 
the available data, it remains debatable whether 
prematurity alone is an independent risk factor 
for PNALD considering the presence of con-
founding variables in premature infants that may 
also infl uence the development of PNALD and 
the lower quality of available studies [ 27 ]. 
 The duration of PN administration is a strong 
predictor of developing PNALD [ 27 ]. In a study 
of surgical neonates, the frequency of PNALD 
was 35 % in those who received PN for at least 
2 weeks, but increased to 58 and 75 % with PN 
administration for at least 30 and 90 days, respec-
tively. All neonates developed PNALD whenever 
PN was given for more than 180 days [ 25 ]. 
 The number of septic episodes in PN patients 
also increases the risk of cholestasis [ 27 ]. In one 
study, surgical neonates had a 30 % increase in 
plasma bilirubin concentrations during recurrent 
episodes of sepsis [ 31 ]. Sepsis may induce cho-
lestasis possibly via the toxic effects of endotoxins 
or lipopolysaccharides on the hepatobiliary sys-
tem. Endotoxin may cause direct hepatocellular 
injury or possibly mediate the formation of cyto-
toxic bile acids and stimulate the release of hepa-
totoxic infl ammatory mediators such as tumor 
necrosis factor (TNF) and interleukins 1 and 6 
[ 23 ]. Endotoxins also downregulate critical cana-
licular transporter proteins, including bile salt 
export protein, which may change the composition 
of bile or result in the accumulation of potentially 
cytotoxic substances within the liver [ 32 – 34 ]. 
 SBS [ 35 ] resulting from extensive resection of 
the small intestine is associated with malabsorption 
and metabolic abnormalities that require long dura-
tion of PN. PNALD including cholestasis, hepatic 
fi brosis, and liver failure are the leading causes of 
death in patients with SBS [ 36 ]. Predisposing fac-
tors to PNALD in SBS patients include prolonged 
duration of PN, reduced intestinal length and loss 
of epithelial barrier integrity, intestinal bacterial 
overgrowth, and abnormal bile acid excretion in 
patients with ileal resection [ 23 ]. The shorter the 
remaining small bowel length, the higher is the risk 
for developing PNALD [ 4 ]. Conversely, for any 
length of small bowel, the presence of cholestasis 
in a child with SBS markedly increases the risk of 
death attributable to PNALD [ 26 ]. 
 Bacterial translocation from the intestinal tract 
especially gram-negative bacteria producing 
endotoxins has been also postulated to be a risk 
factor for PNALD. Animal studies have shown 
that the lack of enteral feeding during PN infusion 
along with intestinal dysmotility leads to bacterial 
overgrowth that causes intestinal infl ammation 
and disruption of the gut barrier. It has been 
hypothesized that intestinal-derived lipopolysac-
charide (LPS) permeates through this disrupted 
gut barrier, enters the portal circulation, and binds 
to Toll-like receptor 4 (TLR4). This leads to 
Kupffer activation, resulting in the release of a 
cascade of proinfl ammatory cytokine signaling in 
early stages of PNALD. Figure  17.1 shows a 
schematic concept of this theoretical mechanism 
driving the development of PNALD. Potentially, 
the use of broad-spectrum antibiotics to suppress 
the intestinal microfl ora or the ablation of TLR4 
signaling may attenuate this liver injury [ 37 ]. 
Combined small bowel atrophy, decreased intesti-
nal immunoglobulin A (IgA) levels, production of 
hepatotoxic cytokines, and disruption of the intes-
tinal microfl ora and bacterial overgrowth all may 
occur as a result of bowel rest. Therefore, bacte-
rial overgrowth combined with intestinal permea-
bility could result in bacterial translocation 
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(passage of intestinal microfl ora from the intes-
tines into the mesenteric lymph nodes, blood, or 
organs) leading to direct toxic effects of bacteria 
on the liver or cytokines causing hepatocyte 
injury. Signifi cant correlation has been reported 
between bacterial overgrowth and cholestasis and 
PN dependence [ 38 ,  39 ]. In 1985, Freund and col-
leagues examined the effect of oral metronidazole 
on hepatic dysfunction during PN administration 
in rats [ 40 ]. The administration of metronidazole 
at a dose of 15 mg/kg/day signifi cantly decreased 
the hepatic lipid content, suggesting the possible 
involvement of anaerobic bacteria as part of the 
multifactorial pathogenesis of PNALD. Although 
the toxic effects of bacterial infections on the liver 
are established, the evidence remains lacking for 
the routine use of oral antibiotic therapy to pre-
vent bacterial translocation and decrease hepato-
cyte damage in PN patients [ 27 ].
 Trace Elements and PNALD 
 Manganese, Copper, and Aluminum 
 Manganese and copper are trace minerals that are 
routinely supplemented in PN. They are mainly 
eliminated via the bile and therefore may accumu-
late during cholestasis. Manganese accumulation 
especially in patients with hyperbilirubinemia 
may have direct toxicity on the canalicular mem-
brane [ 41 ]. In a group of 57 children who received 
PN for more than 14 days, there was a signifi cant 
correlation between blood manganese and plasma 
bilirubin and AST concentrations [ 42 ]. Although 
an association has been reported between elevated 
blood manganese and increased plasma GGT and 
alkaline phosphatase concentrations [ 43 ,  44 ], no 
fi rm conclusion could be drawn that high manga-
nese levels cause cholestasis in PN patients. In 
clinical practice, manganese should be monitored 
on a monthly basis in patients receiving long-term 
PN and restricted if levels are elevated. 
 Although liver toxicity is a feature of copper 
accumulation, copper toxicity has not been 
reported in PN patients. However, copper accumu-
lation may still occur. Autopsies from patients 
with SBS who received copper supplementation in 
their home PN revealed copper accumulation in 
the liver and kidneys, especially in those who died 
of liver failure [ 45 ]. Potentially subclinical copper 
accumulation may occur in home PN patients with 
cholestasis especially when higher copper doses 
are given [ 46 ]. However, copper defi ciencies may 
Lamina propria
monocytes
TLR
TNF-α Loss of
EBF
Intraluminal
bacteria and LPS
Secondary injury
to liver
 Fig. 17.1  Schematic of the potential mechanism which 
may drive the development of PNALD. Loss of epithelial 
barrier function ( EBF ) occurs from a loss of enteral feed-
ing or injury to the bowel from infl ammatory processes 
leading to an upregulation of tumor necrosis factor-alpha 
( TNF-α ) from lamina propria monocytes. This results in 
translocation of bacterial and lipopolysaccharide ( LPS ) 
which pass into the portal venous system and secondarily 
incurs injury to the liver 
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occur and have been reported in PN-dependent 
patients when copper intake is restricted, some of 
which can be lethal [ 47 ]. Copper levels, along with 
clinical markers of copper defi ciency and/or over-
load, should be monitored every 1–3 months for 
patients on long- term PN therapy with the pro-
vided dose adjusted accordingly. While historical 
recommendations indicate empiric reduction in 
manganese and copper provision in PN in the set-
ting of PNALD, current evidence does not support 
this practice. Rather, individualized dosing of 
manganese and copper should be guided by clini-
cal status and measured serum concentrations in 
order to detect any accumulation and prevent any 
toxicity or defi ciency [ 27 ]. 
 Aluminum is a known contaminant of PN 
solutions [ 48 ]. Aluminum accumulation may 
cause bone, liver, blood, and central nervous sys-
tem toxcixicities. Although aluminum-induced 
liver toxicity has been not reported in PN patients, 
animal studies have reported that aluminum in 
PN may induce portal infl ammation and liver 
injury by possibly blunting the bile canaliculi 
microvilli in a way similar to fi ndings in PNALD 
patients [ 49 ,  50 ]. Although the Food and Drug 
Administration has mandated PN component 
product labeling for aluminum and recommended 
maximum daily exposure limits [ 48 ], aluminum 
contamination in PN remains problematic [ 51 ]. 
Therefore, periodic monitoring of serum alumi-
num is recommended especially in patients at 
risk for aluminum accumulation such as prema-
ture infants, PN-dependent patients, and those 
with decreased renal function. 
 Non-pharmacologic Management 
Strategies 
 Early Initiation of Enteral Feeding 
 The most effective therapy for PNALD is 
achievement of enteral nutrition either orally or 
via a feeding tube [ 52 ]. Cholestasis develops 
more commonly in pediatric patients who are 
unable to tolerate any enteral feeding [ 27 ]. 
Enteral feeding exposes the intestinal tract to 
nutrients causing the release of endogenous 
 hormones that promote intestinal epithelial cell 
growth, intestinal adaptation, and reversal of 
mucosal hypoplasia induced by starvation 
[ 23 ,  53 ]. Even small, trophic volumes of feedings 
via continuous administration or small bolus 
amounts have shown clinical benefi t by reducing 
intestinal stasis and translocation of bacteria, 
improving bile fl ow, and avoiding oral aversion 
[ 23 ]. Trophic feeding exposes the intestinal tract 
to nutrient and hormonal stimulation which 
results in intestinal epithelial cell growth, enzyme 
activity, and motility [ 53 ]. Once tolerance to tro-
phic feedings is established, advancing slowly 
toward caloric goal over a period of weeks to 
months may be achieved with a proportional 
decrease in PN administration, as clinically toler-
ated. When intolerances (e.g., abdominal disten-
sion or high stool output of 30–40 mL/kg/day) to 
enteral feedings occur, the rate of enteral feeding 
may be decreased, the enteral formula may be 
changed when indicated, and pharmacologic 
management of diarrhea may be initiated [ 54 ]. If 
dependence on PN is a result of intestinal resec-
tion or SBS, specialized enteral formulas may be 
chosen to optimize nutrient absorption depending 
on the length and segment of the remaining bowel. 
 Cycled Parenteral Nutrition 
 A proposed method for reducing PNALD is 
to “cycle” daily PN infusion, that is, to have a 
PN-free period during the day. Cycling PN pro-
motes the cyclic release of gastrointestinal hor-
mones and better approximates feeding rhythms 
or normal eating patterns that avoids the continu-
ous compulsive effects of nutrients on the liver [ 5 , 
 52 ]. Although originally cyclic PN was used in 
adults to free patients from the infusion apparatus 
especially those on long-term PN, a clinical ben-
efi t of this practice has been also demonstrated 
in its effects on improving serum bilirubin levels 
in PN-dependent patients [ 55 ]. However, main-
taining euglycemia during PN-free periods is a 
concern in young children, especially in neonates 
and infants due to the immaturity of their protec-
tive metabolic functions such as decreased glu-
coneogenesis, glycogenolysis, and  ketogenesis 
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and limited glycogen stores. Nevertheless, it 
remains an approach for stable older infants, 
children, and adolescents for the management of 
PNALD. Cycled PN is achieved by ramping up 
and ramping down the infusion over 1–2 h, with 
the remainder of the volume infused at a con-
tinuous rate over the remaining time of the cycle 
[ 5 ]. For patients who cannot tolerate PN cycling, 
slow advancement of PN cycle (e.g., starting 
with 22-h infusion and then advancing the cycle 
slowly by 2 h every few days) with close moni-
toring is recommended. If cyclic PN is employed, 
it is important to monitor blood glucose control 
throughout the cycle, often by capillary blood 
glucose measurements. One approach is to moni-
tor blood glucose levels three times daily while 
on cycled PN: immediately before the start of PN 
(lowest value), 4 h into the cycle (highest value), 
and 30 min post-PN infusion in order to check 
hypoglycemia at the end of the cycle. Closer 
monitoring of fl uid and electrolyte balance is also 
indicated as the PN cycle is advanced. In general, 
one should avoid cycling PN until at least 25 % of 
nutrients are concomitantly given via the enteral 
route in order to avoid hypoglycemia during PN 
off times. 
 The benefi t of cyclic PN in preventing 
PNALD in young infants receiving PN has not 
been  consistently demonstrated. In a study that 
evaluated the effects of cyclic PN on infants with 
gastroschisis, 107 patients were analyzed, 36 of 
which received a cyclic PN and 71 of which did 
not [ 56 ]. The duration of the PN cycle was ini-
tially 20 h with a dextrose-containing solution 
infused during the off period to avoid hypogly-
cemia. The cycle was extended up to 6–12-h off 
of PN daily as patients grew and became older; 
however, a standard cycle for all included 
patients was not defi ned. The time to onset to 
hyperbilirubinemia was found to be signifi cantly 
longer in those patients receiving cyclic PN as 
compared to those on continuous PN: cycled 
5.7 % (95 % CI 0–13.1 %) versus continuous 
22.3 % (95 % CI 9.9–33 %),  p = 0.005 at 25 days 
of therapy. At any time during the course of PN, 
after adjusting for other confounding factors, 
patients who received continuous PN were 2.86 
times more likely to develop hyperbilirubinemia 
as compared to those patients on cycled PN; 
however, this result was not statistically signifi -
cant. Conversely, in another study of cyclic PN 
in very-low-birth- weight infants (weight 
≤1,250 g), early cycling of PN did not signifi -
cantly reduce the development of cholestasis 
[ 57 ]. Rather, other factors such as duration of PN 
as well as the time to full enteral feedings were 
identifi ed as independent risk factors for the 
development of PNALD. For very young 
patients, if cycling is considered, it cannot be 
implemented unless the patient is already toler-
ating some amount of enteral feedings or a dex-
trose-containing solution is infused during off 
PN times so as to avoid hypoglycemia [ 27 ]. 
 Further, the risks involved with cycling PN in 
critically ill patients including metabolic abnor-
malities such as electrolyte, acid–base, and fl uid 
balance abnormalities make continuous infusion 
preferred in this group of patients [ 58 ]. For older, 
clinically stable patients, or those tolerating con-
comitant enteral administration of nutrients, 
cyclic PN may be a consideration as a preventa-
tive strategy for PNALD and as an improvement 
in quality of life for long-term PN patients. 
 Alternative Lipid Strategies 
 IVFEs are a source of calories and essential fatty 
acids (linoleic and alpha-linolenic acid). 
Currently, the available IVFE products in the 
USA are derived from soybean oil. These formu-
lations have been considered as an independent 
risk factor in the development of PNALD [ 59 ]. 
Interest in intravenous fat emulsion and its asso-
ciation with PNALD has mounted within the last 
decade, and much work has recently been done 
investigating novel approaches to lipid therapy. 
Although the exact mechanism whereby IVFEs 
cause PNALD is not yet fully elucidated, several 
mechanisms have been proposed including the 
effects of proinfl ammatory omega-6 fatty acids 
possibly causing hepatocyte damage or apoptosis 
or the cell membrane peroxidation induced by 
long-chain polyunsaturated fatty acids [ 60 ,  61 ]. 
Soybean-based fat emulsions contain high levels 
of phytosterols, which have been shown to impair 
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bile drainage and contribute to hepatobiliary dys-
function [ 27 ]. Phytosterols are contaminants of 
IVFEs and are ineffi ciently metabolized by the 
liver. The accumulation of one plant phytosterol, 
in particular stigmasterol, may be a major con-
tributor to the development of liver toxicity and 
PNALD by binding to membrane proteins and 
reducing bile synthesis and fl ow [ 62 ]. While liver 
enzyme levels may remain close to normal, liver 
biopsies of patients with high serum plant sterol 
levels have shown liver fi brosis indicating that 
elevated serum plant sterol levels may mirror the 
formation of liver fi brosis, although a defi nite 
cause-effect relationship between phytosterols 
and PNALD has not been proven [ 24 ]. An addi-
tional mechanism by which IVFE may contribute 
to PNALD is that soybean-based fat emulsions 
are rich in omega-6 fatty acids, which may cause 
hepatocyte damage or apoptosis due to a proin-
fl ammatory mechanism [ 27 ]. Due to these factors 
and the available data, several strategies can be 
undertaken to minimize the effects of IVFEs on 
the liver and include (1) soybean-based FE mini-
mization or (2) the use of alternatives IVFE such 
as fi sh oil-based emulsions and combination fat 
emulsions. However, data supporting either 
approach are mostly reliant upon retrospective or 
uncontrolled studies, therefore limiting the 
strength of supporting evidence. Results of stud-
ies for each approach are promising, but long- 
term outcomes and safety data are needed from 
well-designed trials. 
 IVFE Minimization 
 The defi nition of IVFE minimization has not been 
consistently described; however, typically it is 
defi ned as receipt of less than 1 g/kg/day of IVFE 
[ 63 ]. The benefi t of IVFE minimization was fi rst 
described in the adult literature in 1982, by 
Allardyce [ 64 ]. For pediatric patients, this tech-
nique was fi rst described by Colomb et al., in a 
group of ten infants with severe cholestasis [ 65 ]. 
The authors acutely terminated IVFE administra-
tion and noted the marked decline in bilirubin lev-
els in these patients. A follow-up, prospective 
study by Cober and Teitelbaum supported this 
IVFE minimization strategy for the prevention of 
PNALD [ 66 ,  67 ]. In this single-center prospective 
study, patients who developed PNALD (direct 
bilirubin >2.5 mg/dL) on standard soybean-based 
IVFE at a dose of 3 g/kg/day received an IVFE 
regimen of 1 g/kg/day twice weekly. These 
patients were compared to a well- matched his-
torical control group that received standard IVFE 
dosing. Thirty-one patients were evaluated, and 
in the serum direct bilirubin levels in those treated 
with IVFE minimization were found to signifi -
cantly decline over time compared to the control 
group. Specifi cally, the group receiving IVFE 
minimization was found to have a downward 
trend in bilirubin (estimated slope −0.73 mg/dL/
week) as compared to the standard cohort, which 
showed a rise in bilirubin levels across study 
weeks (estimated slope 0.29 mg/dL/week). A 
signifi cant difference in the slopes was identifi ed 
between the groups,  p = 0.0017. Additionally, the 
number of patients achieving resolution of 
PNALD was signifi cantly greater in the IVFE 
minimization group ( n = 13) as compared to the 
control group ( n = 3),  p = 0.013. It is important to 
note that in this study, eight patients developed 
reversible, mild essential fatty acid defi ciency 
(EFAD) while receiving twice weekly IVFE. 
There were no physical manifestations of EFAD 
observed other than biochemical markers (triene-
to-tetraene ratio ≥0.05). For those patients who 
developed EFAD, however, the lipid regimen was 
altered to 1 g/kg/day three days per week and 
then again to 2 g/kg/day three days per week, if 
needed. These changes resulted in resolution of 
EFAD in all patients. Finally, there were no sig-
nifi cant differences in overall growth between the 
two groups. 
 Confl icting results were demonstrated in a ret-
rospective study conducted by Nehra and col-
leagues [ 61 ]. Neonates requiring long-term 
parenteral nutrition support, defi ned as ≥21 days 
of therapy, were divided into two groups: (1) 
[ n = 29] those receiving IVFE at a dose of 1 g/kg/
day and (2) [ n = 32] those receiving IVFE at a 
dose between 2 and 3 g/kg/day and who were 
evaluated for the primary outcome of develop-
ment of cholestasis, defi ned as direct bilirubin of 
>2 mg/dL for ≥2 consecutive weeks. The inci-
dence of cholestasis was not statistically signifi -
cant between the two groups, with 15/29 patients 
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in the group receiving 1 g/kg/day and 14/32 
patients in the group receiving 2–3 g/kg/day 
developing cholestasis,  p = 0.61. Likewise, the 
time to develop cholestasis was found to be simi-
lar between both groups. In this study, once cho-
lestasis developed, patients were expeditiously 
attempted to transition to full enteral feeds or 
transitioned to a fi sh oil-based fat emulsion. A 
limitation to this study is its retrospective nature 
as well as slight differences in study populations 
between the two groups. 
 These two studies regarding IVFE minimiza-
tion reveal important, but confl icting, fi ndings 
relevant to reduced doses of fat emulsion and the 
effect on prevention of PNALD. Each study has 
its own limitations, and several questions still 
remain regarding this approach to treatment such 
as optimal dose of IVFE, timing of initiation of 
IVFE minimization, as well as short- and long- 
term outcomes as well as the safety associated 
with this treatment approach. These questions 
may be answered in a well-designed prospective 
study that randomizes patients in a matched fash-
ion to IVFE minimization and standard therapies 
in order to evaluate effectiveness of this strategy 
in reducing the development of PNALD. These 
studies must also be designed to evaluate 
 important fi ndings such as EFAD, growth restric-
tion, and both short- and long-term neurodevel-
opmental effects. 
 Use of Fish Oil-Based IVFE 
 In contrast to soybean-based fat emulsions which 
contain omega-6 fatty acids, fi sh oil-based emul-
sions are almost completely omega-3 fatty acids, 
which are believed to have several benefi cial 
effects and to play a role in the resolution of 
PNALD [ 63 ]. The benefi ts of fi sh oil-based 
emulsions in preventing PNALD as compared to 
soybean- based IVFEs may be due to several fac-
tors which include a reduction in detrimental 
phytosterols and proinfl ammatory mediators. 
Fish oil FE may have an additive benefi t of being 
a substrate for the formation of a favorable pros-
taglandin composition and also contain an 
antioxidant alpha-tocopherol, which has immu-
nomodulatory effects. The only available fat 
emulsion composed of fi sh oil is Omegaven ®  
(Fresenius Kabi Deutschland GmbH, Bad 
Homburg, Germany). A recent study that com-
pared Omegaven to four other fat emulsions in a 
murine model demonstrated that inclusion of 
fi sh oil had positive effects on hepatic outcomes 
[ 68 ]. The fi rst clinical report of fi sh oil-based 
emulsion, published in 2006, demonstrated com-
plete reversal of PNALD in two infants with 
intestinal failure-associated liver disease [ 69 ]. 
The clinical utility has subsequently been dem-
onstrated in several case reports [ 70 – 76 ]. Further, 
the use of fi sh oil-based emulsion was studied in 
42 infants who developed PNALD while receiv-
ing soybean- based FE who were predicted to 
require PN for a minimum of 30 days [ 77 ]. These 
infants were compared to a cohort of 59 infants 
that received standard soybean-based fat emul-
sion. Infants who received fi sh oil-based fat 
emulsion received it at a dose of 1 g/kg/day, 
whereas the historical cohort received soybean-
based fat emulsion at a dose ranging from 1 to 
4 g/kg/day. Direct bilirubin levels decreased over 
time in the fi sh oil cohort as compared to an 
increase in levels seen in the standard soybean 
cohort ( p < 0.0001). Forty-fi ve percent ( n = 19) of 
the patients in the fi sh oil group versus 4.1 % 
( n = 2) in the soybean oil group demonstrated 
reversal of cholestasis during the study period. 
Further, the risk of death or the need for trans-
plantation was lower in the group receiving fi sh 
oil-based fat emulsion. From a safety standpoint, 
fi sh oil-based emulsion was, overall, well toler-
ated with fewer patients developing hypertri-
glyceridemia; however, two patients did develop 
EFAD in the fi sh oil group. Continued safety has 
been substantiated with continued use under a 
compassionate-use open study [ 78 ]. This study 
is limited by its short follow- up period as well as 
the fact that a quarter of the patients received PN 
for less than 3 weeks [ 77 ]. Additionally, it is not 
known whether the benefi cial effects were due to 
the fi sh oil emulsion itself or due to the reduced 
dose (1 g/kg/day) of fat emulsion. However, a 
prospective randomized trial is underway that 
will examine conventional soybean oil-based fat 
emulsion versus fi sh oil-based fat emulsion at a 
goal dose of 1 g/kg/day, which may help to 
answer this question. 
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 Another study evaluated the effects of fi sh oil 
IVFE on 12 children with SBS and severe 
PNALD (direct bilirubin >2.9 mg/dL) [ 79 ]. 
Study results showed that nine patients had com-
plete resolution of hyperbilirubinemia within 
24 weeks of treatment. Four of these patients 
were receiving a combination of fi sh oil and soy-
bean oil, whereas fi ve patients were receiving 
fi sh oil alone. Despite the small sample size, 
results indicate a possible clinical use of com-
bined fi sh- and soybean-based IVFE to prevent 
PNALD while preserving adequate caloric and 
fatty acid intake. Combination fat emulsion may 
more closely approximate the optimal fatty acid 
intake and may lead to more physiologic out-
comes as well as benefi ts in growth and develop-
ment [ 63 ]. 
 While not intravenous, the use of enteral fi sh 
oil has also recently been examined and deserves 
a brief mention [ 80 ,  81 ]. While benefi ts were 
seen in a small subset of patients, the use of 
enteral fi sh oil relies on at least a partially func-
tional intestine. Therefore, the benefi cial effects 
may be confounded by the fact that a functional 
intestine may also tolerate enteral feeds and dem-
onstrate intestinal adaptation [ 63 ]. Therefore, 
resolution of PNALD may be due to improved 
intestinal adaptation and tolerance of enteral 
feeds rather than the presence of enteral fi sh oil. 
 Composite Intravenous Fat Emulsion 
Formulation 
 In addition to single-component fat emulsions, a 
few novel fat emulsions have been developed. 
SMOFlipid (Fresenius Kabi) is a combination fat 
emulsion that contains soybean oil, medium- 
chain triglycerides, olive oil, as well as fi sh oil 
resulting in an omega-6 to omega-3 fatty acid 
ratio of 2.5:1 [ 63 ]. While SMOFlipid is not cur-
rently available in the USA, several studies have 
shown safety and effi cacy of this emulsion [ 82 –
 85 ]. A study of 28 children between the ages of 
5 months and 11 years requiring long-term home 
PN compared the liver effects of SMOFlipid and 
standard soybean-based fat emulsion at a target 
dose of 2 g/kg/day [ 82 ]. At 4 weeks, patients who 
received SMOFlipid had lower mean serum con-
centrations of ALT, AST, and GGT as compared 
with the soybean-based IVFE group. Further, the 
mean change in serum total bilirubin was signifi -
cantly greater in the SMOFlipid group ( p < 0.01) 
with a decrease seen in the SMOFlipid group as 
compared with an increase in the standard fat 
emulsion group. In addition to these benefi ts, 
several case series have been published that dem-
onstrate a reversal of elevated direct bilirubin 
with the use of SMOFlipids [ 86 – 88 ]. 
 IVFEs available outside of theUSA, such as 
Lipofundin MCT (B. Braun), which is a combi-
nation of soy and coconut oil, and  Clinoleic 
(Baxter), which is a combination of olive and soy 
oils, may also play a role in the management of 
PNALD [ 63 ]. There have been a few clinical 
studies evaluating the effi cacy of these agents; 
however, more data is warranted before use of 
these agents can be universally recommended. 
The American Society of Parenteral and Enteral 
Nutrition recently published a position paper on 
alternative fat emulsions, which calls for 
expanded availability of and further research on 
the alternative fat emulsions so that the ideal for-
mula may be identifi ed for special patient popu-
lations [ 89 ]. 
 Pharmacologic Management 
 Phenobarbital 
 Phenobarbital is a barbiturate, a sedative hyp-
notic, and an anticonvulsant medication that has 
been used to stimulate choleresis in patients with 
various forms of cholestatic liver disease [ 90 ]. 
For the treatment of PNALD, several theoreti-
cal mechanisms exist. Its effect is thought to be 
associated with the activation of enzymes, which 
stimulate the fl ow of bile [ 91 ,  92 ]. Additionally, 
phenobarbital may increase bile salt produc-
tion, decrease serum bile acids and bilirubin, 
increase the conjugation of bilirubin and acceler-
ate hepatic clearance of bile acids, and possibly 
affect the hepatic activity of the Na, K-ATPase 
pump [ 92 ,  93 ]. In an early case report, pheno-
barbital effi cacy was demonstrated 36 h after 
phenobarbital initiation at a dose of 5 mg/kg/day 
in a patient with progressive liver disease and 
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 cirrhosis secondary to PNALD [ 93 ]. However, 
despite its theoretical benefi t and effectiveness 
seen in individual cases, other case reports have 
not shown similar benefi t. A retrospective study 
performed in 1986 evaluated the effects of phe-
nobarbital in PN-dependent neonates weighing 
less than 1,500 g [ 92 ]. Two groups of patients 
were evaluated: (1) those who received parenteral 
nutrition ( n = 21) and (2) those who received par-
enteral nutrition plus phenobarbital at an initial 
intravenous dose of 5 mg/kg/day with therapeu-
tic drug monitoring to maintain serum phenobar-
bital concentrations between 15 and 25 mcg/dL 
( n = 10). For infants who received phenobarbital 
therapy, indications included seizure treatment 
or prophylaxis. Interestingly, more patients in 
the phenobarbital group developed PNALD as 
compared to those who did not receive phenobar-
bital (60 % vs. 33 %). Thus, phenobarbital did 
not offer protection against the development of 
PNALD and, in fact, may have contributed to its 
development [ 91 ,  92 ]. 
 The use of phenobarbital for the treatment of 
PNALD has fallen out of favor due to confl icting 
and minimal evidence supporting its use, in addi-
tion to advancements made in other more effi ca-
cious therapies. However, in severe cases, 
phenobarbital may be considered on an individ-
ual basis when other alternatives are not possible 
or have been exhausted. Patients should be moni-
tored for possible phenobarbital-associated 
adverse effects such as hypotension, bradycardia, 
respiratory depression, sedation, and thrombo-
phlebitis with intravenous use and vitamin D 
defi ciency especially with extended use, to name 
a few [ 90 ]. 
 Ursodiol 
 Ursodiol, or ursodeoxycholic acid, is a hydro-
philic dihydroxylated bile acid, which typically 
comprises a small fraction (1–3 %) of the second-
ary bile acid pool in humans, is released by the 
gallbladder, and is then solubilized and absorbed 
in the jejunum and terminal ileum, respectively 
[ 94 ,  95 ]. After oral administration of exogenous 
ursodiol, passive absorption in the small and 
large intestines (30–60 %) and the colon (20 %) 
results, followed by conjugation in the liver, 
secretion into the biliary tree and the intestines, 
and then extensive enterohepatic recirculation 
and reabsorption in the terminal ileum [ 94 – 96 ]. 
While the exact mechanism of action of ursodiol 
in the treatment of PNALD is unknown, pro-
posed mechanisms include correction of bile acid 
defi ciency, improvement in and stimulation of 
bile fl ow, and displacement of toxic hydrophobic 
bile acids such as chenodeoxycholic acid, in 
addition to the provision of immunomodulatory 
and cytoprotective effects [ 94 ,  95 ,  97 – 99 ]. 
During chronic administration, ursodiol becomes 
the primary biliary and plasma bile acid, ulti-
mately displacing cytotoxic bile acids and 
increasing bile secretion and fl ow [ 95 ,  96 ,  100 ]. 
 After administration of ursodiol (10–30 mg/
kg/day in 2–3 divided doses) to pediatric patients 
with PNALD, a marked and sustained improve-
ment in liver biochemistry levels has been dem-
onstrated, including direct bilirubin, serum ALT, 
aspartate aminotransferase (AST), alkaline phos-
phatase (ALP), and gamma-glutamyl transpepti-
dase (GGT), with the earliest improvements seen 
in direct bilirubin and GGT [ 100 – 102 ]. 
Ursodeoxycholic acid has shown to decrease the 
extent and duration of PNALD in both medical 
and surgical populations and in very-low-birth- 
weight infants, neonates, infants, and older chil-
dren and in those children with short bowel 
syndrome (SBS). By and large the results have 
been positive, with results showing a decreased 
extent and the duration of PNALD [ 101 – 105 ]. 
Early response may be seen within the fi rst 
2 weeks of therapy; however, complete resolu-
tion may take up to 4 months [ 102 ]. Interestingly, 
in a recent prospective study, those children with 
SBS had an earlier and more pronounced 
response to ursodiol as compared to those chil-
dren without SBS, indicating that even those 
children with signifi cant intestinal loss respond 
well to treatment with ursodiol at a higher dose of 
30 mg/kg/day in divided doses [ 105 ]. 
 Tauroursodeoxycholic acid (TUDCA), an 
agent similar to ursodeoxycholic acid, was evalu-
ated by Heubi et al. in a prospective, random-
ized clinical trial designed to evaluate TUDCA’s 
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 prophylactic effects on lowering peak conju-
gated bilirubin levels in infants on long-term PN 
[ 106 ]. The dose evaluated was 30 mg/kg/day in 
two divided doses. Study results showed that 
TUDCA was ineffective in preventing or reduc-
ing the severity of PNALD in neonates. Further 
studies may be needed to further delineate the 
role of TUDCA in the treatment and prevention 
of PNALD. 
 The timing of initiation of ursodiol therapy 
has yet to be fully defi ned, and a major limitation 
is that the drug must be given enterally. While 
some centers may initiate at the earliest signs of 
cholestasis, others wait until full enteral feeding 
has been achieved. However, evidence suggests 
benefi t with initiation at the earliest onset of 
PNALD, if enteral tolerance is possible [ 104 , 
 105 ]. While there is no consensus on the minimal 
amount of enteral feeds required prior to initiat-
ing oral ursodiol, it may be recommended to 
achieve tolerance of at least 5 mL/h prior to initi-
ating oral medications. Likewise, the optimal 
duration of therapy is still unknown. A rebound 
rise in markers of cholestasis may be seen after 
discontinuation of ursodiol; however, normaliza-
tion occurs after re-initiation of therapy [ 105 ]. In 
general, ursodiol is very well tolerated; however, 
mild diarrhea has been described in some cases. 
The long-term effect of ursodiol on progression 
and prognosis on PNALD is unknown. Further, it 
is uncertain how the well-controlled study on 
TUDCA failed to show effi cacy, where the less 
controlled studies were benefi cial. Thus, evi-
dence from large, prospective, randomized, and 
placebo-controlled studies is still needed. 
 Other Therapies 
 Cholecystokinin-octapeptide (CCK-OP) is the 
active portion of cholecystokinin gastrointestinal 
peptide that can improve intrahepatic bile fl ow 
[ 107 ]. Although early investigations showed prom-
ise for the role of CCK-OP in the management of 
PNALD [ 107 – 109 ], later larger well- designed 
studies showed no clinical role of CCK-OP in 
the prevention or treatment of PNALD. In a 
 double-blind, multicenter, randomized control 
trial  conducted at eight centers, CCK was stud-
ied in a total of 243 infants at a dose of 0.04 mcg/
kg intravenously twice daily and failed to show a 
signifi cant effect in conjugated bilirubin lev-
els, incidence of sepsis, time to enteral feedings, 
length of intensive care unit stay, or hospital length 
of stay [ 110 ]. Since that time, no additional tri-
als have been published with alternative dosing 
strategies or differing results [ 27 ]. Thus, routine 
use of CCK is not recommended for treatment of 
PNALD in pediatric patients. 
 Glutamine, one of the most abundant amino 
acids in the plasma and human milk, has been 
suggested as an exogenous supplement to reduce 
sepsis, enhance gastrointestinal integrity, and 
improve immune function [ 111 ]. Glutamine sup-
plementation may also have protective effects on 
the liver, especially in those patients receiving 
long-term PN through the increase of glutathione 
stores in the liver. In 2010, the effects of intrave-
nous glutamine supplementation on hepatic func-
tion and mortality and the time to full enteral 
nutrition were evaluated in 28 neonates. 
Signifi cant decreases in total bilirubin and AST 
concentrations were observed in patients supple-
mented with glutamine, although no other study 
endpoints were found to be signifi cant. The 
effects of enteral glutamine are currently being 
investigated. At this time, however, the routine 
use of parenteral or enteral glutamine, for the 
prevention or treatment of PNALD, is not recom-
mended until substantive data are available. 
 Amino acids such as cysteine and taurine have 
been presumed to be nonessential in older chil-
dren and adults; however, they are conditionally 
essential in neonates and infants [ 112 ]. However, 
taurine defi ciencies have been noted in individu-
als with short bowel syndrome receiving long- 
term PN, and taurine is needed for the successful 
conjugation of bilirubin to bilirubin diglucuro-
nide. Thus, efforts to increase plasma taurine lev-
els have been investigated. One investigation by 
Helms et al. revealed that plasma taurine concen-
trations may be selectively increased with the 
addition of cysteine (40 mg/g of amino acids) to 
infant parenteral nutrition [ 112 ]. Supplemental 
taurine has also been investigated in the setting of 
PNALD [ 113 ]. In a multicenter, prospective 
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study conducted between 1996 and 2001, the 
effect of supplemental taurine on the develop-
ment of PNALD was evaluated. When evaluated 
overall, taurine did not demonstrate benefi t; how-
ever, when stratifi ed by gestational age and indi-
cation, taurine showed benefi t in those patients 
who were premature and those with a history of 
necrotizing enterocolitis (NEC). Specifi cally, the 
conjugated bilirubin was reduced in premature 
infants receiving taurine 0.5 mg/dL [0.17–1.18] 
versus 3.45 mg/dL [1.79–5.11] in those not 
receiving taurine,  p = 0.07. For those patients 
with NEC, conjugated bilirubin was 4.04 mg/dL 
[2.85–5.23] in those receiving taurine versus 
8.29 mg/dL [5.61–10.96] in those who did not 
receive taurine,  p = <0.01. Therefore, the investi-
gators concluded that taurine supplementation 
may be benefi cial in a subset of higher risk 
patients but may also be considered as a standard 
in all neonatal amino acid solutions. 
 Prevention and Treatment of Sepsis 
 Recurrent sepsis has been closely associated with 
the development or worsening of PNALD [ 31 ]. 
Recurrent sepsis was associated with a 30 % 
increase in bilirubin levels. Thus, several strate-
gies can be undertaken to decrease the risk or fre-
quency of sepsis in patients on long-term PN. 
The prevention of sepsis should be a priority in 
the treatment of patients dependent on 
long-term PN. 
 Enteral Antibiotics 
 For patients on long-term PN, translocation of 
bacteria from a disused intestine increases the 
risk of systemic and catheter-related bloodstream 
infections (CRBSIs) due to decreased gut barrier 
integrity [ 114 ,  115 ]. The theory that lack of intes-
tinal stimulation during periods of prolonged 
fasting and PN administration may lead to a 
change in the gut microbiology (i.e., microbiota) 
and increased risk of bacterial translocation 
 possibly leading to sepsis has led to the use of 
enteral antibiotics to treat intestinal microbial 
overgrowth and ultimately prevent bacterial 
translocation. However, this practice is not uni-
versally accepted due to a relative lack of evi-
dence-based data. While intravenous medications 
such as metronidazole have not been shown to be 
effective [ 116 ], cycled enteral antibiotics (CEA) 
as a preventative strategy have demonstrated effi -
cacy. Eradication of abnormal fl ora, selective 
decontamination via CEA, may be considered in 
high risk patients, such as patients with missing 
ileocecal valve and those with frequent episodes 
of bacteremia or CRBSIs [ 115 ,  117 ]. While it is 
recognized that total eradication of intestinal bac-
teria is not possible, therapy should be aimed at 
reducing symptoms as well as decreasing abnor-
mal fl ora as well as decreasing the number of 
potential pathogens. There are several approaches 
to CEA. Typically CEA is a combination or suc-
cessive administration of enteral antibiotics, fol-
lowed by an antibiotic-free period, which allows 
the microbiota of the gut to recover [ 115 ]. In a 
recent study by Dobson and colleagues, the use 
of enteral metronidazole 7.5 mg/kg three times 
daily for 2 weeks, followed by a combination of 
enteral colistin 25 mg four times daily with 
enteral tobramycin 20 mg four times daily for 
2 weeks, followed by a 2-week antibiotic-free 
period before restarting the cycle, was retrospec-
tively evaluated in pediatric patients receiving 
PN for at least 28 days [ 115 ]. A signifi cant reduc-
tion in sepsis rates for those patients treated with 
CEA was observed. 
 The ideal choice of enteral antibiotics has not 
yet been fully elucidated; however, the combina-
tion should target organisms typically found in 
the gut, such as anaerobes (i.e., metronidazole, 
amoxicillin-clavulanate) and gram-negative 
organisms (i.e., aminoglycosides, ciprofl oxacin, 
or colistin). In some cases, antifungal coverage 
(i.e., fl uconazole, nystatin) may be considered. 
Preferably, the combination of antibiotics should 
be nonabsorbable from the gut so as to limit sys-
temic exposure and minimize adverse effects. 
One approach may be to continuously administer 
a combination of antibiotics, while a second 
approach consists of sequential, cyclic adminis-
tration of antibiotics with an antibiotic-free 
period in between cycles. 
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 Antibiotic-Lock Therapy 
 Catheter-related bloodstream infections (CRBSIs) 
account for a major source of morbidity and mor-
tality among patients receiving long- term paren-
teral nutrition. Indeed, the National Nosocomial 
Infections Surveillance System notes that CRBSIs 
occur 2.7–9.1 per 1,000 catheter days, on average 
[ 118 ]. Systemic treatment with antibiotics may 
last from 7 to 21 days, depending on the type of 
infection, and treatment success rates are less than 
100 %, due to diffi culty in eradication of organ-
isms from biofi lms that form in the catheter lumen 
[ 119 ]. The biofi lm is a protein-fi brin matrix that, 
in essence, traps bacteria and then allows for bac-
terial duplication and continued shedding into the 
bloodstream [ 120 ]. One technique that may be 
employed to prevent diffi cult infections is antibi-
otic-lock technique, a technique that involves fi ll-
ing the central venous access device with a 
specifi c antibiotic solution. The antibiotic is in 
direct contact with the catheter lumen and thus the 
biofi lm, allowing for greater eradication of infec-
tious pathogens, typically in a shorter amount of 
time (i.e., 1–2 weeks) [ 121 ]. The Infectious 
Diseases Society of America recognizes this tech-
nique as an approach to treating and salvaging 
central venous access devices [ 122 ]. 
Implementation of this technique requires knowl-
edge of the infectious organism for treatment, and 
for prophylaxis, the decision to use a specifi c anti-
biotic based on previous infection history dictates 
the antibiotic of choice. There are many types of 
antibiotic-lock therapy, typically consisting of 
vancomycin, gentamicin or tobramycin, or fl uco-
nazole, to name a few. Solutions usually contain 
an anticoagulant such as heparin, as well, in order 
to maintain catheter patency as well as aid in deg-
radation of the fi brin sheath in the biofi lm layer 
[ 121 ]. Antibiotic-lock therapies have been studied 
in several patient populations with long-term 
indwelling central venous access devices with 
overall favorable results. 
 Ethanol-Lock Therapy 
 In addition to targeted antibiotic-lock therapy, the 
use of ethanol-lock therapy has been shown to be 
an effective therapy to prevent infections [ 114 ]. 
Ethanol-lock therapy was fi rst introduced in 2003 
for use in oncology patients; however, use has 
expanded to include several other patient popula-
tions, including those patients with intestinal 
failure-associated liver disease (IFALD) on long- 
term PN [ 123 ,  124 ]. Ethanol is antimicrobial and 
fungicidal (protein denaturation) as well as fi bri-
nolytic (prevention of fi brin sheath formation) at 
concentrations ranging from 40 to 100 %, and it 
offers the advantage of covering multiple organ-
isms rather than targeting specifi c organisms with 
specifi c antibiotic-lock therapy [ 125 ,  126 ]. The 
risk of development of antimicrobial resistance is 
also limited with the use of ethanol-lock rather 
than antibiotic-lock therapy. A meta-analysis 
published in 2012 evaluated the use of ethanol- 
lock therapy as compared to heparin-lock therapy 
in a total of 53 patients from four observational 
studies [ 114 ]. Overall, while some variability 
exists in study methods, a 70 % ethanol solution 
dwelled in the catheter for at least 2 h ranging 
from daily to 3 days per week at a volume of 
0.2–3 mL is reported. The results of the meta- 
analysis revealed a mean rate difference of 
CRBSIs of 7.67 (95 % CI 5.87, 9.47;  p < 0.0001) 
and a reduction in risk of CRBSIs by 81 % (RR 
0.19, 95 % CI 0.12, 0.32;  p < 0.0001). Despite 
these more robust fi ndings, the combined results 
revealed only weak evidence that ethanol-lock 
therapy decreases the need for catheter replace-
ment. The number needed to treat (NNT) in 
included studies in the meta-analysis ranged 
from 108 to 150 ethanol-lock days to prevent one 
CRBSI, a clinically relevant effect. Interestingly, 
the microbiological cause of infection, when 
infections do occur while receiving ethanol-lock 
therapy, may be altered, as demonstrated by 
Cober et al. [ 127 ]. Specifi cally, infections were 
caused by  Staphylococcus aureus and  S .  epider-
midis only, rather than by some of the more com-
mon pathogens such as  Enterococcus spp., 
 Escherichia coli ,  Pseudomonas aeruginosa , 
 Klebsiella pneumonia , and  Candida spp. 
 Safety concerns with ethanol-lock therapy 
include the loss of catheter integrity as well as 
systemic exposure to ethanol. Ethanol’s effect on 
both polyurethane and silicone catheters has been 
reported in the literature; reports of a lower 
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breakage force as well as decreased elasticity 
have been reported [ 114 ]. The clinical signifi -
cance of these observations is not yet known; 
however, the greater observed effects on polyure-
thane have led to avoidance of concomitant use 
with polyurethane catheters and to limit use of 
ethanol-lock therapy to silicone-based catheters 
only [ 125 – 128 ]. Additionally, ethanol-lock ther-
apy has not been well studied in peripherally 
inserted central venous catheters or implantable 
ports [ 126 ]. It is of the utmost importance to 
determine the type of catheter a patient has prior 
to initiating ethanol-lock therapy. Similarly, the 
clinical signifi cance of systemic exposure to 
small volumes of ethanol is unknown. One study 
allowed systemic fl ushing of ethanol without 
reported adverse effects [ 126 ]; however, it is rec-
ommended to withdraw the ethanol solution 
whenever able [ 125 ]. Of note, upon administra-
tion of the fi rst dose of ethanol-lock therapy, the 
solution must be withdrawn to prevent introduc-
tion of bacteria into the patient after initial 
 disruption of the biofi lm layer [ 127 ]. Furthermore, 
Cober et al. provide estimated blood ethanol lev-
els if the entire ethanol lock is infused into 
patients, which allows for a targeted safety mar-
gin where the ethanol-lock volume will not 
exceed half of the anticipated intoxication blood 
level [ 127 ]. Finally, by limiting use to patients 
who weigh at least 5 kg, systemic effects of etha-
nol, should exposure occur, will be limited [ 125 , 
 127 ,  128 ]. Additionally, studies have not reported 
any observable signs or symptoms of intoxication 
[ 126 ,  127 ]. Other adverse effects of ethanol- lock 
therapy are rare and may include thrombotic 
events [ 114 ,  126 – 129 ]. 
 Ethanol-lock therapy is typically compounded 
using a 98 % dehydrated ethanol, USP, and sterile 
water for injection to make a fi nal concentration 
of 70 % ethanol [ 125 ,  127 ]. This solution has 
been found to be stable at room temperature for 
up to 14 days [ 130 ]. It is incompatible with citrate 
and heparin, so catheters must be fl ushed with 
normal saline before and after administration in 
order to prevent incompatibilities [ 130 ]. The vol-
ume of the ethanol lock should be individualized 
based on the volume of the patient’s central 
venous access device. This may be done by aspi-
rating from the catheter until blood return is 
noted and then using this volume plus 0.1–0.2 mL 
as the ethanol-lock volume [ 125 ,  127 ]. 
 Supportive data for ethanol-lock therapy 
comes mainly from retrospective studies as well 
as case reports and case series. More robust data 
from randomized, controlled trials is warranted. 
It has been suggested that these studies should 
focus on the lowest effective concentration of 
ethanol, optimal dwell time, optimal administra-
tion regimen (i.e., daily vs. 3 days/week), as well 
as clinically relevant side effects [ 129 ]. At this 
time, ethanol-lock therapy is not endorsed by the 
Infectious Diseases Society of America, despite 
published convincing data; however, it is noted 
that supporting evidence is growing and the role 
in prevention in CRBSI is becoming clearer 
[ 122 ]. Interestingly, in a recent investigation that 
evaluated the effects of a national shortage of the 
ethanol product used to compound medicinal 
ethanol-lock therapy (98 % dehydrated ethanol), 
failure of CRBSI prophylaxis was demonstrated 
when use was rationed, further supporting the use 
of this therapeutic modality [ 131 ]. 
 Surgical Options 
 Surgical therapy in intestinal failure consists of 
maintaining bowel length at initial presentation 
and subsequent autologous intestinal reconstruc-
tive surgery. In those patients in whom bowel 
adaptation does not occur and whose liver dis-
ease progresses while on parenteral nutrition, 
small bowel or multivisceral transplantation 
remains the therapeutic option. 
 Bowel Conservation 
 Patient outcomes in intestinal failure (IF) patients 
are dependent on the remaining length of the 
small bowel [ 26 ,  132 ]. But the combination of 
PNALD and loss of small bowel represents an 
additive risk factor for mortality in infants with 
SBS (Fig.  17.2 ) [ 26 ]. It is, therefore, crucial at ini-
tial operation that every effort be made to main-
tain as much bowel length as possible. This often 
requires multiple explorations with the resection 
of only frankly necrotic bowel at each procedure. 
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Enteral feeds allow intestinal adaptation and 
bowel growth that can allow for expedited wean-
ing from PN. The process of adaptation, however, 
often results in signifi cant small bowel dilation 
with those segments characterized by poor transit 
and signifi cant stasis [ 133 ]. While ostomies are 
often crucial in the management of neonates and 
children with SBS, early ostomy closure can 
improve electrolyte and fl uid balance and has 
been shown to be associated with a faster wean 
from PN [ 134 – 136 ]. Other derangements that 
occur in IF include decreased intestinal transit 
time that can lead to stasis, bacterial overgrowth, 
and malabsorption as well as diarrhea and electro-
lyte derangements. These problems cannot always 
be treated adequately with supplementation or 
changes in enteral formulas. Surgical interven-
tions in IF are aimed at eliminating or minimizing 
these complications with an ultimate goal of 
restoring enteral autonomy [ 133 ].
 Autologous Intestinal Reconstruction 
Surgery 
 While the goals of early surgical and continued 
medical management in IF involve maintaining 
bowel length, initiating early enteral feeds, and 
avoiding the potentially fatal complications of 
long-term PN, a signifi cant number of children 
will progress to surgical therapy in an attempt to 
increase their bowel length [ 137 ]. Surgical bowel 
lengthening is primarily indicated when children 
have reached a plateau in the ability to advance 
enteral feeding and a continued dependence on 
PN [ 136 ]. 
 Over the years numerous surgical procedures 
have been used to increase bowel length and/or 
slow intestinal transit time. Earliest among these 
procedures were reversed intestinal segments, 
recirculating bowel loops, colonic interposition, 
as well as tapering or plicating dilated bowel seg-
ments [ 138 – 141 ]. Intestinal tapering as a primary 
surgical modality in pediatric IF is often not an 
option given the signifi cant number of patients 
with limited short bowel length. Most of the 
promising data regarding reversed intestinal seg-
ments was obtained in dogs, and although some 
successful data exist for adults, these results were 
not replicated in children perhaps because the 
preferred length of bowel to be used was variable 
across procedures [ 142 ,  143 ]. Recirculating 
bowel loops involved creation of a circular loop 
of bowel to effectively increase mucosal surface 
area and allow for increased nutrient absorption. 
These procedures, however, were often compli-
cated by obstruction, volvulus, and stasis that 
limited their widespread use [ 139 ,  144 ]. Colonic 
interposition procedures – which involved insert-
ing an isoperistaltic segment of colon along the 
small bowel length – were fi rst described in dogs 
before being applied to children [ 140 ,  145 ]. 
Success in these fi rst case series to be reported 
were mixed and related to the remnant small 
bowel length as well as the length of colon which 
was interposed [ 146 ,  147 ]. Long-term success in 
the pediatric population using this procedure has 
not been defi ned although some isolated case 
reports exist that show that, at least in isolated 
instances, success is possible [ 148 ,  149 ]. Due to 
the complex nature of some of these procedures 
as well as only modest clinical success, these 
have essentially been replaced by a variety of 
autologous intestinal reconstruction procedures 
with small bowel transplantation remaining a 
viable option in children with progressive liver 
disease and PN dependence [ 150 ,  151 ]. 
 Autologous intestinal reconstruction surgery 
(AIRS) consists of a number of different surgical 
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procedures, all of which use the patient’s own 
bowel to improve length and absorptive capacity. 
The three main AIRS procedures in use today 
include the Bianchi procedure and its modifi ca-
tions, the Iowa procedure, and the serial trans-
verse enteroplasty (STEP). 
 The longitudinal intestinal lengthening and 
tailoring operation (LILT) was fi rst described by 
Bianchi in 1980 [ 152 ]. This procedure takes 
advantage of the fact that the small bowel is sup-
plied by a mesentery which can be divided in half 
without compromising intestinal blood supply. In 
order to perform a Bianchi procedure, the mesen-
tery is carefully divided into its two halves along 
the length of dilated small bowel. The bowel is 
then stapled to create two new lumens along the 
mesenteric sheets. The bowel is then anasto-
mosed in an isoperistaltic manner. The result is a 
doubled length of bowel of half its original 
 diameter. The obvious benefi ts of this procedure 
include its ability to easily double the length of 
small bowel and to halve its diameter – in this 
manner dramatically increasing the mucosal 
absorptive surface available to nutrients and 
decreasing the stasis and potential bacterial over-
growth of intestinal contents. The biggest draw-
back to this procedure is the technical skill 
required and the increased morbidity inherent in 
the number of bowel anastomoses required as 
well as the suture or staple line along the small 
bowel [ 153 ]. In addition, the Bianchi procedure 
can only be performed once on a given segment 
of bowel given its reliance on longitudinal divi-
sion of the mesentery [ 154 ]. Numerous authors 
have reported long-term success using this proce-
dure although complications consisting of adhe-
sive bowel obstruction, anastomotic strictures, 
and redilation of the involved bowel are not 
uncommon [ 133 ,  155 – 157 ]. A modifi cation of 
the original Bianchi procedure has been reported 
which decreases the number of anastomoses 
required, but details of the long-term success of 
this procedure have not yet been reported in the 
literature [ 153 ].
 The most recently developed and widely used 
intestinal lengthening procedure is the serial 
transverse enteroplasty (STEP) [ 158 ]. In this 
technique a stapling device is used to create alter-
nating mesenteric and antimesenteric divisions in 
a length of dilated small bowel (Fig.  17.3 ). The 
advantages of this procedure are that it both 
lengthens and tapers dilated small bowel, it is 
relatively easy to perform, and it can be used in a 
bowel that does not exhibit uniform dilation [ 159 , 
 160 ]. Other advantages include the ability to 
repeat the procedure when the small bowel, 
invariably, dilates again [ 154 ,  161 ,  162 ]. Using a 
registry of STEP procedures performed world-
wide, long-term results were published in 2007. 
In this cohort of 38 patients from 19 centers, 
small bowel length was increased from 68 ± 44 cm 
pre-STEP to 115 ± 87 cm post-STEP, a relative 
increase of 67 %. All but three patients had 
improved enteral nutrition tolerance following 
the procedure. Operative complications were 
considered relatively minor and consisted of 
leakage from a staple line in two patients and two 
bowel obstructions that were managed conserva-
tively. Five patients developed progressive liver 
dysfunction and were referred for  transplantation. 
Three patients died of progressive liver failure 
and/or sepsis [ 160 ]. A second report on the long-
term outcomes of the STEP procedure demon-
strated that these children exhibit improved 
STEP procedure
Pre-lengthening
Post-lengthening
 Fig. 17.3  Diagram showing the pre- and postoperative 
appearance of small bowel before and after serial trans-
verse enteroplasty (STEP) procedure (Reproduced with 
permission from Keith Georgeson) 
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growth parameters including increased weight-
for- age, height-for-age, and weight-for-height Z 
scores [ 159 ,  163 ]. Two reports have been pub-
lished that describe the ability to repeat the STEP 
procedure following a previous lengthening pro-
cedure [ 154 ,  162 ].
 Conclusion/Summary 
 In summary, PNALD remains a serious and 
potentially life-threatening disease process. While 
it appears that the mechanisms of action may be 
multifactorial, many approaches can impact the 
severity of this disease. Concerted efforts to mod-
ify intravenous fat emulsion administration, 
reduce the incidence of bacterial translocation, 
and prevent the occurrence of sepsis, use of bile 
acid therapies and conserve intestinal length all 
can effectively reduce or even prevent the devel-
opment of this very diffi cult hepatic process. 
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